The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Positive-strand RNA viruses replicate their genomes using virally encoded RNA-dependent
RNA polymerases (RdRP) with a common active-site structure and closure mechanism upon …

Remdesivir is an adenosine analogue that has a cyano substitution in the C1′ position of
the ribosyl moiety and a modified base structure to stabilize the linkage of the base to the …

The nucleic acid polymerase-catalyzed nucleotidyl transfer reaction associated with
polymerase active site closure is a key step in the nucleotide addition cycle (NAC). Two …

Abstract Background and Aims Hepatitis E virus (HEV) is one of the most common causes of
acute hepatitis worldwide. Its positive‐strand RNA genome encodes three open reading …

Nucleotide addition cycle (NAC) is a fundamental process utilized by nucleic acid
polymerases when carrying out nucleic acid biosynthesis. An induced-fit mechanism is …

In continuation of our efforts of finding novel nucleoside inhibitors for the treatment of viral
diseases, we initiated a discovery research program aimed at identifying novel nucleos (t) …

The urgent response to the COVID-19 pandemic required accelerated evaluation of many
approved drugs as potential antiviral agents against the causative pathogen, severe acute …

The nucleoside analog remdesivir (RDV) is an FDA-approved antiviral for the treatment of
SARS-CoV-2 infections, and as such it is critical to understand potential genetic …

The binding of the active form of Remdesivir (RTP) to RNA-dependent RNA Polymerase
(RdRp) of SARS-CoV-2 was studied using molecular dynamics simulation. The RTP …